MARKET

APGE

APGE

Apogee Therapeutics Inc
NASDAQ
82.08
+3.81
+4.86%
Opening 12:46 05/20 EDT
OPEN
79.40
PREV CLOSE
78.27
HIGH
82.26
LOW
79.00
VOLUME
332.89K
TURNOVER
--
52 WEEK HIGH
95.32
52 WEEK LOW
34.34
MARKET CAP
6.19B
P/E (TTM)
-18.9488
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APGE last week (0511-0515)?
Weekly Report · 2d ago
Apogee Therapeutics CEO Michael Henderson disposes 20,000 common shares worth $1.64 million
PUBT · 4d ago
APOGEE THERAPEUTICS INC <APGE.O>: JEFFERIES RAISES TARGET PRICE TO $120 FROM $100
Reuters · 6d ago
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Reuters · 6d ago
Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Apogee Therapeutics (APGE)
TipRanks · 05/13 01:50
Apogee Therapeutics (APGE) Gets a Buy from Wedbush
TipRanks · 05/12 14:25
Analysts Offer Insights on Healthcare Companies: Oculis Holding (OCS) and Apogee Therapeutics (APGE)
TipRanks · 05/12 13:31
Canaccord Genuity Sticks to Their Buy Rating for Apogee Therapeutics (APGE)
TipRanks · 05/12 11:06
More
About APGE
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.

Webull offers Apogee Therapeutics Inc stock information, including NASDAQ: APGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APGE stock methods without spending real money on the virtual paper trading platform.